Pharma cold chain — temperature, location and chain of custody.
Pharma cold chain compliance under DSCSA, EU FMD, GDP and 21 CFR Part 11 is no longer optional. The technology that delivers it is sensor-rich BLE or LoRaWAN tags with on-device temperature logging, fed into an audit-grade event stream that regulators can verify in seconds.
What regulatory compliance actually requires.
DSCSA (US Drug Supply Chain Security Act) — serialised item-level traceability across the supply chain to the dispensing point. Implementation deadline already past for most categories.
EU FMD (Falsified Medicines Directive) — serialisation and verification at point of dispense.
GDP (Good Distribution Practice) — temperature control with audit-grade evidence across distribution.
21 CFR Part 11 — electronic records with audit trail, time-stamp, user attribution, no retrospective edit.
The deliverable is not just a system that records temperature — it is a system that proves the recording chain is unbroken and tamper-evident.
The technology stack that delivers compliance.
Sensor-rich BLE tags with on-device temperature logging, accelerometer (shock), light sensors (tamper). Battery life 12–36 months depending on duty cycle.
LoRaWAN sensor tags for distribution-vehicle and long-haul logging where BLE range is insufficient.
Active RFID in warehouse and DC environments for asset-level location of cold storage equipment.
GNSS / cellular for end-to-end shipment tracking with temperature overlay.
Audit-grade platform with time-stamped event log, user attribution, 21 CFR Part 11-compliant record-keeping.
Where cold chain implementations fail.
Tag-to-platform handoff at warehouse boundaries — warehouse BLE reads need to merge cleanly with distribution-truck LoRaWAN logs without data gaps.
Temperature excursion event handling — what counts as an excursion, who is notified, what is the auto-quarantine workflow.
Audit trail completeness — a single gap in the chain undermines the entire compliance case. Vendor implementations often have edge-case gaps that pass commissioning and fail audit.
Integration into ERP / EWM / WMS — lot-level traceability has to flow to inventory systems, not just sit in a separate dashboard.
Independent advisory through implementation.
Vendor-neutral platform selection — the right blend of sensor hardware, gateway infrastructure and audit platform for your specific drug category and distribution model.
Validation pack design — URS, FRS, IQ, OQ, PQ documentation that maps to the regulator's expectation.
Audit-readiness assessment — gap analysis against your actual current state before regulator inspection.
See our cold chain practice for the engagement model.
Who else sells pharma cold chain — and what GDP programmes get wrong.
Logger and visibility platforms — Controlant, Sensitech/Berlinger, ELPRO, and cellular IoT peers — own much of the lane-monitoring conversation. Warehouse and packaging sites separately buy Passive RFID portals, environmental monitoring systems and, less often, RTLS for high-value returns or quarantine cages. Quality teams then discover the evidence pack spans three vendors with three identity schemes.
What programmes get wrong: validating loggers while dock-door custody and serialisation handoffs remain paper; treating real-time alerts as quality control without clear excursion ownership; over-instrumenting lanes that are already statistically stable; and letting a device reseller write the “risk assessment” that happens to recommend their SKU volume.
We stay device-neutral. Advisory covers GDP-aligned monitoring architecture, integration to WMS/ERP/QMS, and where site RFID/RTLS closes custody gaps — coordinated with cold-chain services when implementation support is needed.
What GDP-ready cold-chain locating and monitoring require together.
Inspection-ready cold chain is a custody story, not a logger catalogue. Lane risk assessment should drive where real-time IoT loggers, periodic indicators, fixed chamber sensors and site RFID/RTLS each earn their keep. Over-instrumenting stable lanes creates alert fatigue; under-instrumenting dock handoffs and quarantine cages creates the findings that hurt.
Identity must survive the journey: serialisation or batch IDs, logger IDs and pallet/tote IDs need a join key that quality can defend. When warehouse Passive RFID portals already scan shipments, cold-chain events should reuse that identity rather than inventing a parallel barcode moment. Excursion workflows need named owners, time-bound disposition rules and QMS linkage — a dashboard alert without a closed CAPA trail is theatre.
Vendor validation packages are necessary and not sufficient. Challenge whether the operating model covers power loss, door-ajar discipline, courier handoff and returns. Device-neutral advisory separates logger selection from architecture so volume discounts cannot rewrite the risk assessment. Site RTLS is rarely the first buy; it appears where high-value returns, segregated storage or packaging suites need zone accountability beyond a logger point reading.
Acceptance: excursion closure time, percent of shipments with complete custody evidence, and successful mock inspection using the live systems — not a slide deck of logger specs.
Where packaging and returns cages sit inside the same building as ambient logistics, zone discipline matters as much as logger choice: mix-ups at the wrong door create excursions no sensor can prevent. Design dock and cage events so quality sees a single custody timeline — logger, portal and human handoff — before the next inspection asks for it under time pressure.
Who else sells pharma cold chain — and what GDP programmes get wrong.
Logger and visibility platforms — Controlant, Sensitech/Berlinger, ELPRO, and cellular IoT peers — own much of the lane-monitoring conversation. Warehouse and packaging sites separately buy Passive RFID portals, environmental monitoring systems and, less often, RTLS for high-value returns or quarantine cages. Quality teams then discover the evidence pack spans three vendors with three identity schemes.
What programmes get wrong: validating loggers while dock-door custody and serialisation handoffs remain paper; treating real-time alerts as quality control without clear excursion ownership; over-instrumenting lanes that are already statistically stable; and letting a device reseller write the “risk assessment” that happens to recommend their SKU volume.
We stay device-neutral. Advisory covers GDP-aligned monitoring architecture, integration to WMS/ERP/QMS, and where site RFID/RTLS closes custody gaps — coordinated with cold-chain services when implementation support is needed.
What GDP-ready cold-chain locating and monitoring require together.
Inspection-ready cold chain is a custody story, not a logger catalogue. Lane risk assessment should drive where real-time IoT loggers, periodic indicators, fixed chamber sensors and site RFID/RTLS each earn their keep. Over-instrumenting stable lanes creates alert fatigue; under-instrumenting dock handoffs and quarantine cages creates the findings that hurt.
Identity must survive the journey: serialisation or batch IDs, logger IDs and pallet/tote IDs need a join key that quality can defend. When warehouse Passive RFID portals already scan shipments, cold-chain events should reuse that identity rather than inventing a parallel barcode moment. Excursion workflows need named owners, time-bound disposition rules and QMS linkage — a dashboard alert without a closed CAPA trail is theatre.
Vendor validation packages are necessary and not sufficient. Challenge whether the operating model covers power loss, door-ajar discipline, courier handoff and returns. Device-neutral advisory separates logger selection from architecture so volume discounts cannot rewrite the risk assessment. Site RTLS is rarely the first buy; it appears where high-value returns, segregated storage or packaging suites need zone accountability beyond a logger point reading.
Acceptance: excursion closure time, percent of shipments with complete custody evidence, and successful mock inspection using the live systems — not a slide deck of logger specs.
Where packaging and returns cages sit inside the same building as ambient logistics, zone discipline matters as much as logger choice: mix-ups at the wrong door create excursions no sensor can prevent. Design dock and cage events so quality sees a single custody timeline — logger, portal and human handoff — before the next inspection asks for it under time pressure.
Frequently asked questions
What is the difference between DSCSA and EU FMD for cold chain?
Both require serialisation. DSCSA is US-focused, EU FMD is European. The implementation details differ — serialisation data format, hub architecture, verification model — but the underlying RTLS / sensor stack is largely the same.
Do we need sensor tags or can we use truck-level loggers?
Depends on the drug category and packaging. High-value or sensitive product typically needs item-level or pallet-level sensors. Standard cold-chain logistics often acceptable at truck-level. The regulator’s expectation is documented.
Which platforms have been audited successfully?
We work vendor-neutrally across the main players. Successful audits are determined by validation pack quality and event-stream completeness more than by platform brand.
How long does cold chain implementation take?
Discovery to operational compliance typically 6–18 months depending on scope. Validation alone often 8–16 weeks. The implementation timeline is decided by validation rigour, not by physical install.
Last updated: